Vaccines (Feb 2024)

Impact of Antenatal SARS-CoV-2 Exposure on SARS-CoV-2 Neutralization Potency

  • Chia-Jung Chiang,
  • Wei-Lun Hsu,
  • Mei-Tsz Su,
  • Wen-Chien Ko,
  • Keng-Fu Hsu,
  • Pei-Yin Tsai

DOI
https://doi.org/10.3390/vaccines12020164
Journal volume & issue
Vol. 12, no. 2
p. 164

Abstract

Read online

A pregnancy booster dose significantly reduces the risk and severity of COVID-19, and it is widely recommended. A prospective cohort study was conducted to compare the transplacental passage of maternal antibodies from vaccination or infection during three trimesters against both the vaccine-targeted Wuhan strain and the Omicron strain of SARS-CoV-2. Maternal–infant dyads from vaccinated mothers were collected between 6 June 2022 and 20 September 2022. We analyzed 38 maternal–infant dyads from mothers who had been infected with COVID-19 and 37 from mothers without any previous infection. Pregnant women who received their last COVID-19 vaccine dose in the third trimester exhibited the highest anti-spike protein antibody levels and neutralizing potency against both the Wuhan strain and Omicron BA.2 variant in their maternal and cord plasma. Both second- and third-trimester vaccination could lead to a higher level of neutralization against the Wuhan and Omicron strains. COVID-19 infection had a negative effect on the transplacental transfer ratio of SARS-CoV-2 antibodies. A booster dose during the second or third trimester is encouraged for the maximum transplacental transfer of humoral protection against COVID-19 for infants.

Keywords